1055927-86-0

Basic information

• Product Name: 3-(4-methyl-1-piperazinyl) benzoyl chloride
• Synonyms: 3-(4-methyl-1-piperazinyl) benzoyl chloride
• CAS NO: 1055927-86-0
• Molecular Weight: 238.717
• Mol File: 1055927-86-0.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 3-(4-methyl-1-piperazinyl) benzoyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(4-methyl-1-piperazinyl) benzoyl chloride(1055927-86-0)
• EPA Substance Registry System: 3-(4-methyl-1-piperazinyl) benzoyl chloride(1055927-86-0)

Safety Data

• Hazardous Substances Data: 1055927-86-0(Hazardous Substances Data)

Upstream product

• 215309-01-6 3-(4-methyl-1-piperazinyl)benzoic acid 
• 474334-89-9 methyl 3-(4-methylpiperazin-1-yl)benzoate 

Downstream Products

• 1055925-78-4 N'-{2-cyano-9-[3-(dimethylamino)propyl]-9H-purin-6-yI}-N'-cyclopentyl-3-(4-methyl-1-piperazinyl)benzohydrazide trifluoroacetate 
• 1055925-75-1 N'-(2-cyano-9-methyl-9H-purin-6-yI)-N'-cyclohexyl-3-(4-methyl-1-piperazinyl)benzohydrazide trifluoroacetate 
• 1055925-66-0 N'-(2-cyano-9-methyl-9H-purin-6-yI)-N'-cyclopentyl-3-(4-methyl-1-piperazinyl)benzohydrazide trifluoroacetate 
• 1327167-29-2 N-(3-(3-[(phenylsulfonyl)amino]phenyl)-1H-pyrazol-5-yl)-3-(4-methylpiperazino)benzamide 
• 1055925-77-3 N'-{2-cyano-9-[3-(dimethylamino)propyl]-9H-purin-6-yI}-N'-cyclopentyl-3-(4-methyl-1-piperazinyl)benzohydrazide 
• 1055925-74-0 N'-(2-cyano-9-methyl-9H-purin-6-yI)-N'-cyclohexyl-3-(4-methyl-1-piperazinyl)benzohydrazide 
• 1055925-65-9 N'-(2-cyano-9-methyl-9H-purin-6-yI)-N'-cyclopentyl-3-(4-methyl-1-piperazinyl)benzohydrazide 
• 1055925-88-6 N'-{2-cyano-9-[2-(dimethylamino)ethyl]-9H-purin-6-yl}-N'-cyclopentyl-3-(4-methyl-1-piperazinyl)benzohydrazide 
• 937012-20-9 tert-butyl N-[3-(4-methylpiperazin-1-yl)benzoyl]glycinate 

Relevant articles and documents

Design, synthesis, biological evaluation and pharmacophore model analysis of novel tetrahydropyrrolo[3,4-c]pyrazol derivatives as potential TRKs inhibitors

The tropomyosin receptor kinases TRKs are responsible for different tumor types which caused by NTRK gene fusion, and have been identified as a successful target for anticancer therapeutics. Herein, we report a potent and selectivity TRKs inhibitor 19m through rational drug design strategy from a micromolar potency hit 17a. Compound 19m significantly inhibits the proliferation of TRK-dependent cell lines (Km-12), while it has no inhibitory effect on TRK-independent cell lines (A549 and THLE-2). Furthermore, kinases selectivity profiling showed that in addition to TRKs, compound 19m only displayed relatively strong inhibitory activity on ALK. These data may indicate that compound 19m has a good drug safety. Partial ADME properties were evaluated in vitro and in vivo. Compound 19m exhibited a good AUC values and volume of distribution and low clearance in the pharmacokinetics experiment of rats. Finally, a pharmacophore model guided by experimental results is proposed. We hope this theoretical model can help researchers find type I TRK inhibitors more efficiently.

Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them

The present invention is directed to compounds of the formula or pharmaceutically acceptable salts, prodrug, solvate or optical isomer thereof, pharmaceutical compositions containing same and use thereof for treating diseases linked to disregulated cell p